Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|October 21, 2009
Sage Submissions Releases New eCTD Template Support for EMEA Module 1
Advertisement
Sage Submissions
has released Sage Templates, version 1.1.3. Sage Templates OneVoice feature enables documents to be created across the organization and by outside authors with a consistent look-and-feel. This enables the creation of consistent formatted submissions instead of several formats and document navigation structures.
Extensive customer input was gathered to enhance the design of Sage Templates and to extend the number of templates available to authors of submission documents with Version 1.1.3. Sage Templates are available as a complete set for all stages of submissions in North American and Europe and includes:
· US eCTD
· EU eCTD
· IND
· CTA-IMPD templates for Europe and
· CTA-A templates for Canada
Templates are also available as subsets to provide a low cost acquisition point for companies that prepare Drug Master Files, CROs that conduct nonclinical or clinical studies, or companies that submit only IND, CTA-IMPD or CTA-A submissions.
Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval
5